We supply high purity Lapatinib API and its intermediates, which is for the treatment of advanced or metastatic breast cancer. They are Lapatinib base (231277-92-2); Lapatinib Ditosylate MonohydrateI (388082-78-8); 3-Chloro-4-(3-fluoro-benzyloxy)-phenylamine (202197-26-0); N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine (231278-20-9).
If you have any questions, please contact with us directly!
Cas 202197-26-0,Lapatinib Intermediates,Jp Lapatinib Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com
The collaboration between neuroConn and US-based Soterix Medical has developed a new solution based on the DC-STIMULATOR MC and the Soterix Software HDTargetsTM, which allows for targeted, optimized HD stimulation. Systematic optimization using some small electrodes and application currents to achieve high efficiency and targeted stimulation while ensuring patient safety. This new product is designed to expand current research areas to improve the tDCS clinical research protocol for the treatment of depression, stroke, tinnitus, and pain . Several European universities have acquired new systems. We expect to achieve the first scientific result in 2012.
Recent advances in neuroConn transcranial electrical stimulation and neurocognitive feedback
In March 2012, the new DC-STIMULATOR PLUS will be ready for use.
Ilmenau, January 2012: The new generation of DC-STIMULATOR PLUS, which was developed by us with a significant increase in signal quality, will be put into use at the end of March 2012. In addition to the expansion of basic functions, such as simple choice of system language (German or English), constant impedance check and acoustic error signals, there will be some new software and hardware to open new areas of application.
The SIGNAL OUT option is unique: combined with the new neuroConn software and the Neuro PR A X ® EEG amplifier. It allows EEG to be derived during tDCS and tACS because the induced noise of the stimulus is filtered from the online and real-time EEG signals. The physician can trigger the DC-STIMULATOR PLUS in any signal form with a new option REMOTE via an external voltage generator.
The current Patient Mode is replaced by a time-controlled SCHED-ULE mode that allows the physician to set and control an accurate treatment schedule. Although the various new features will not affect the base price. However, the new DC-STIMULATOR PLUS will replace the current version. Targeted transcranial HD-stimulation. The current clinical paradigm uses two relatively large electrodes to inject current through the head, resulting in an electric field widely distributed in most areas of the brain.
In addition, MATLAB/.NET-library is now available for DC-STIMULATOR MC, with MATLAB or NET Framework.
Serious social impact - EFIC Conference 2011
Hamburg, Germany, September 2011: Serious social impact. This is the slogan of the 7th EFIC Conference in Hamburg. Twenty percent of Europeans suffer from chronic diseases, and these people have more than 100 million people in the European Union. Despite the current medical development and advanced painkillers, there are still many people who cannot be completely cured. In addition to the pain and disability that patients must overcome, the annual medical cost of migraine is €27 billion in Europe. The EFIC conference in Hamburg, Europe, showed the results of the study, predicting the practicality of new drugs that lack safety concerns in the next two years in front of 4,000 participants. In addition, scientists expect to reduce pain in new ways of neuromodulation, which reduces migraine and combined headaches and has no side effects. There are currently at least four methods of development that may cure migraine or combined headaches, Professor Schoenen (Luettich, Germany) explained. Transcranial magnetic stimulation and transcranial DC stimulation are two of them.
tDC S has shown promising results in the latest psychiatric and neurological studies.
Recent scientific studies at Ludwig-Maximilians- University in Munich, Germany , and the University of New Blue Wales in Australia have allowed transcranial direct current stimulation (tDCS) to express insights into efficacy in the treatment of depression. The results of the two studies showed that tDCS had a significant effect on the positive stimuli of participants for up to 20 minutes in one day. Compared with the sham-stimulated group, these participants felt that their subjective emotions were significantly improved compared with before treatment. Researchers at the two universities suggested further research and development of tDCS as an effective treatment for depression.
After treating the positive effects of stroke, such as convulsions, aphasia, or severe memory loss, new studies of tDCS have shown success for the first time in motor capacity improvement. Japanese scientists applied tDCS during functional training or lower limb strength training and found that anodic stimulation can temporarily increase maximal knee extension. A US research survey initiated by James W. Stinear and colleagues first described how DC stimulation enhances the spontaneous control of paralyzed joints. These findings may be beneficial for recovery after a stroke.
THERA PRAX®: Neurological feedback from ADHD
Ilmenau, January 2012: Clinical studies over the past few years have provided clear evidence for the efficacy of neurofeedback in the treatment of ADHD in children. 2 randomized, controlled studies ( Ute Strehl et. al., 2006 and  Holger Gevensleben, et. al., 2009) demonstrated the validity and specificity of ADHD neurofeedback . Subsequent meta-analysis of 15 studies was published in time ( Martjin Arns & Ute Strehl, 2009) found great influence on neural feedback, impulsive and negligent. The moderate efficacy of ADHD is good compared to the effect of the drug entity methylphenidate used in some ADHD medications (Martjin Arns, 2010). Only the drugs here have proven to be more effective. Two follow-up studies can provide evidence to compare with medication. The apparent effects of neural feedback do not disappear even after months or even years after completing the neural feedback training. ( Cihan Gani et. Al., 2008 and Holger Gevensleben et. al., 2009) .
The research team of the German Göttingen psychologist Holger Gevensleben was recently awarded the 2011 Outstanding ECAP-ADHD-Paper Award, which indicates that the follow-up study above is the best publication for ADHD in 2010. The research award, awarded by the European Children's & Adolescent Neurology (ECAP) magazine, sponsored by the German county, emphasizes that the pharmaceutical industry's interest in neurofeedback has developed very well and is increasingly accepted as an adjuvant therapy.
The major children's international associations and adolescent psychology in Germany, the United Kingdom, Europe, the United States and Australia all mention neurological feedback on ADHD guidelines and recommend further research. On the other hand, the American Academy of Pediatrics recently extended the age and medication for children diagnosed with ADHD to only four years old.
In the future, a multi-center study (Ham, Germany), directed by Martin Holtmann experts in Germany, will use PR A X ® therapy to detect the specific effects of ADHD neurofeedback in a random, controlled program. A total of 144 patients from 5 centers were included at the end of 2012. Half of them have been included at the end of 2010. The German Research Foundation (DFG) supported the study with 1.4 million euros.
PRAX® Therapy: The Best Device for Research and ADHD Therapy
P R A X ® therapy can perform neurofeedback and biofeedback (option) of slow cortical potential and EEG. It is now assumed that SCP training in patients with ADHD causes long-term effects, and the determination of CNV can predict the success of treatment. Because SCP training is necessary to remove eye movements from the signal. This is only possible with PR A X ® therapy.
Niels Birbaumer, who originally developed SCP training at the University of Tübingen in Germany, has been working closely with neuroConn for more than 15 years, which has enabled advanced equipment for neurofeedback to incorporate the latest clinical research and progress.
EMG, ADHD SCP training and other standard protocols for indications transmitted to the system were developed by clinical evaluation and appraisal studies.
More than 70 pediatrics, psychology and ergotherapeutical European practices are now using PRAX® therapy for brainwave self-regulation training and have helped many children and adolescents with ADHD to reduce or even discontinue medication.